What is TriSalus Life Sciences' operating income?

TriSalus Life Sciences' total operating income in 2025 was -$26.95 million, based on the following breakdown: Total Gross Profit: $38.19 million Total Operating Expenses: $65.13 million

TriSalus Life Sciences (TLSI) Financials

$3.89 +0.21 (+5.71%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$3.88 -0.01 (-0.13%)

As of 07/9/2026 07:58 PM Eastern

Compare

Annual Income Statements for TriSalus Life Sciences

This table shows TriSalus Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	4.77	-50	-64	-33	-70
Consolidated Net Income / (Loss)	4.77	-47	-59	-30	-39
Net Income / (Loss) Continuing Operations	4.77	-47	-59	-30	-39
Total Pre-Tax Income	4.77	-47	-59	-30	-39
Total Operating Income	-3.04	-36	-54	-36	-27
Total Gross Profit	0.00	10	16	25	38
Total Revenue	0.00	12	19	29	45
Operating Revenue	-	12	19	29	45
Total Cost of Revenue	0.00	2.26	2.61	4.10	6.97
Operating Cost of Revenue	-	2.26	2.61	4.10	6.97
Total Operating Expenses	3.04	47	70	61	65
Selling, General & Admin Expense	3.04	12	24	18	21
Marketing Expense	-	13	17	26	29
Research & Development Expense	-	21	30	18	15
Total Other Income / (Expense), net	7.81	-11	-4.88	6.13	-12
Interest Expense	-	0.00	0.02	3.09	5.54
Interest & Investment Income	0.06	0.18	0.43	0.40	0.56
Other Income / (Expense), net	7.74	-11	-5.29	8.81	-7.29
Income Tax Expense	0.00	0.01	0.01	0.01	0.01
Preferred Stock Dividends Declared	-	2.83	4.24	3.19	30
Basic Earnings per Share	$0.30	($161.55)	($6.77)	($1.31)	($1.84)
Weighted Average Basic Shares Outstanding	31.25M	309.61K	9.40M	25.33M	37.90M
Diluted Earnings per Share	$0.30	($161.55)	($6.77)	($1.31)	($1.84)
Weighted Average Diluted Shares Outstanding	31.25M	309.61K	9.40M	25.33M	37.90M
Weighted Average Basic & Diluted Shares Outstanding	31.25M	8.20M	-	32.27M	61.31M

This table shows TriSalus Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-1.88	-36	-14	-5.13	-3.20	-11	-11	-9.00	-41	-8.33	1.54
Consolidated Net Income / (Loss)	-1.43	-36	-13	-4.33	-2.40	-10	-10	-8.29	-11	-9.75	1.54
Net Income / (Loss) Continuing Operations	-1.43	-36	-13	-4.33	-2.40	-10	-10	-8.29	-11	-9.75	1.54
Total Pre-Tax Income	-1.43	-36	-13	-4.33	-2.40	-10	-10	-8.29	-11	-9.75	1.54
Total Operating Income	-19	-14	-12	-8.17	-8.74	-7.57	-7.33	-7.33	-9.01	-3.27	-8.41
Total Gross Profit	4.60	5.14	5.49	6.45	6.35	7.05	7.67	9.41	9.66	11	7.67
Total Revenue	5.19	5.72	6.46	7.36	7.35	8.26	9.17	11	12	13	8.90
Operating Revenue	5.19	5.72	6.46	7.36	7.35	8.26	9.17	11	12	13	8.90
Total Cost of Revenue	0.59	0.58	0.97	0.91	1.00	1.22	1.50	1.80	1.91	1.76	1.23
Operating Cost of Revenue	0.59	0.58	0.97	0.91	1.00	1.22	1.50	1.80	1.91	1.76	1.23
Total Operating Expenses	23	19	17	15	15	15	15	17	19	15	16
Selling, General & Admin Expense	9.03	6.04	4.63	3.96	4.73	4.66	5.25	5.66	6.66	4.17	5.45
Marketing Expense	4.69	5.60	6.69	6.00	6.14	7.01	6.73	7.16	6.84	7.97	7.41
Research & Development Expense	9.51	7.80	5.84	4.67	4.22	2.95	3.02	3.92	5.18	2.57	3.22
Total Other Income / (Expense), net	17	-21	-1.53	3.85	6.34	-2.53	-3.04	-0.96	-1.79	-6.48	9.95
Interest Expense	0.00	0.00	0.00	0.88	1.14	1.07	1.21	1.42	1.46	1.45	1.44
Interest & Investment Income	0.12	0.24	0.09	0.10	0.16	0.06	0.07	0.13	0.17	0.18	0.16
Other Income / (Expense), net	17	-22	-1.62	4.63	7.32	-1.52	-1.91	0.33	-0.50	-5.21	11
Income Tax Expense	0.00	0.00	0.00	0.01	-0.00	-0.00	0.01	-0.00	0.01	-	0.00
Preferred Stock Dividends Declared	0.46	0.80	0.80	0.80	0.80	0.78	0.71	0.71	30	-1.43	0.00
Basic Earnings per Share	($0.14)	$29.78	($0.60)	($0.21)	($0.12)	($0.38)	($0.39)	($0.27)	($0.96)	($0.22)	$0.03
Weighted Average Basic Shares Outstanding	13.17M	9.40M	23.32M	23.90M	26.50M	25.33M	28.53M	32.90M	43.06M	37.90M	51.54M
Diluted Earnings per Share	($0.14)	$29.78	($0.60)	($0.21)	($0.12)	($0.38)	($0.39)	($0.27)	($0.96)	($0.22)	$0.03
Weighted Average Diluted Shares Outstanding	13.17M	9.40M	23.32M	23.90M	26.50M	25.33M	28.53M	32.90M	43.06M	37.90M	52.31M
Weighted Average Basic & Diluted Shares Outstanding	26.32M	0.00	27.16M	29.31M	30.49M	32.27M	37.84M	49.87M	49.96M	61.31M	61.42M

This table details how cash moves in and out of TriSalus Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-1.13	-21	2.46	-3.25	12
Net Cash From Operating Activities	-1.74	-32	-51	-41	-18
Net Cash From Continuing Operating Activities	-1.74	-32	-51	-41	-18
Net Income / (Loss) Continuing Operations	4.77	-47	-59	-30	-39
Consolidated Net Income / (Loss)	4.77	-47	-59	-30	-39
Depreciation Expense	-	0.40	0.68	0.74	0.63
Amortization Expense	-	-	0.00	0.61	1.05
Non-Cash Adjustments To Reconcile Net Income	-7.81	12	18	8.63	15
Changes in Operating Assets and Liabilities, net	1.30	2.19	-9.76	-21	4.81
Net Cash From Investing Activities	0.06	-1.79	-1.59	-0.35	-0.84
Net Cash From Continuing Investing Activities	0.06	-1.79	-1.59	-0.35	-0.84
Purchase of Property, Plant & Equipment	-	-0.66	-0.59	-0.35	-0.92
Sale of Property, Plant & Equipment	-	-	-	0.00	0.08
Net Cash From Financing Activities	0.54	13	55	38	31
Net Cash From Continuing Financing Activities	0.54	13	55	38	31
Repayment of Debt	0.00	-	0.00	-2.59	-0.52
Repurchase of Common Equity	0.00	0.00	-0.02	0.00	-1.55
Issuance of Debt	0.54	-	0.00	25	10
Issuance of Common Equity	0.00	-	0.00	16	22
Other Financing Activities, net	-	-0.04	45	-0.01	0.43
Cash Interest Paid	-	-	0.02	1.75	3.70
Cash Income Taxes Paid	0.00	0.01	0.01	0.02	0.02

This table details how cash moves in and out of TriSalus Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	17	-9.51	-7.81	13	-5.19	-2.76	4.48	13	-3.80	-2.25	36
Net Cash From Operating Activities	-22	-9.18	-11	-13	-11	-5.71	-4.50	-7.32	-3.71	-2.48	-6.48
Net Cash From Continuing Operating Activities	-22	-9.18	-11	-13	-11	-5.71	-4.54	-7.32	-3.71	-2.65	-6.48
Net Income / (Loss) Continuing Operations	-1.48	-36	-13	-4.33	-2.40	-10	-10	-8.29	-11	-9.75	1.54
Consolidated Net Income / (Loss)	-1.48	-36	-13	-4.33	-2.40	-10	-10	-8.29	-11	-9.75	1.54
Depreciation Expense	0.16	0.19	0.18	0.19	0.18	0.19	0.17	0.17	0.16	0.13	0.14
Amortization Expense	0.13	-0.13	0.00	0.42	0.02	0.41	0.24	0.58	-0.31	0.28	0.30
Non-Cash Adjustments To Reconcile Net Income	4.07	13	-1.34	10	-3.13	2.51	3.01	2.32	7.39	2.08	-1.34
Changes in Operating Assets and Liabilities, net	-25	14	3.51	-20	-5.51	1.30	2.42	-2.09	-0.14	4.61	-7.11
Net Cash From Investing Activities	-1.11	-0.37	-0.07	-0.06	-0.17	-0.05	-0.71	0.09	-0.18	-0.04	-0.14
Net Cash From Continuing Investing Activities	-1.11	-0.37	-0.07	-0.06	-0.17	-0.05	-0.71	0.09	-0.18	-0.04	-0.14
Purchase of Property, Plant & Equipment	-0.18	-0.37	-0.07	-0.06	-0.17	-0.05	-0.75	0.09	-0.22	-0.04	-0.14
Sale of Property, Plant & Equipment	-	-	0.00	-	-	-	0.04	-	0.04	-	0.00
Net Cash From Financing Activities	40	0.04	3.13	26	5.82	2.99	9.69	21	0.08	0.28	42
Net Cash From Continuing Financing Activities	40	0.04	3.13	26	5.82	2.99	9.69	21	0.08	0.28	42
Repayment of Debt	-	-	0.00	-2.59	-	-	-0.52	-	-	-	-0.26
Issuance of Debt	-	-	0.00	25	-	-	10	-	-	-	0.00
Issuance of Common Equity	-	-	3.14	3.60	5.84	2.95	0.00	22	-	0.19	43
Other Financing Activities, net	40	0.06	-0.02	-0.02	-0.02	0.04	0.21	0.06	0.08	0.08	0.02
Cash Interest Paid	-	-	0.00	0.45	1.31	-	0.71	0.85	0.97	1.17	1.14
Cash Income Taxes Paid	-	-	0.00	0.00	-	-	0.00	0.02	-	-	0.00

This table presents TriSalus Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	252	251	22	25	24	35
Total Current Assets	2.01	0.53	17	21	21	32
Cash & Equivalents	1.33	0.20	9.41	12	8.53	20
Accounts Receivable	-	-	1.56	3.55	5.09	6.56
Inventories, net	-	-	1.47	2.55	4.05	3.08
Prepaid Expenses	0.67	0.33	4.77	2.99	3.01	2.17
Plant, Property, & Equipment, net	0.00	0.00	2.23	2.09	1.67	1.81
Total Noncurrent Assets	250	250	2.55	1.65	1.63	1.28
Other Noncurrent Operating Assets	250	250	1.75	1.65	1.63	1.28
Total Liabilities & Shareholders' Equity	252	251	22	25	24	35
Total Liabilities	23	17	34	52	50	69
Total Current Liabilities	0.10	1.60	32	15	10	11
Accounts Payable	0.10	1.06	4.95	3.39	2.27	3.00
Accrued Expenses	-	-	6.38	11	7.36	8.10
Other Current Liabilities	-	0.00	21	0.74	0.60	0.40
Total Noncurrent Liabilities	23	16	1.96	37	40	58
Long-Term Debt	-	0.00	-	0.00	22	33
Other Noncurrent Operating Liabilities	23	16	1.96	37	18	25
Commitments & Contingencies	0.00	0.00	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-21	-17	-176	-27	-26	-34
Total Preferred & Common Equity	-21	-17	-176	-27	-26	-34
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-21	-17	-176	-27	-26	-34
Common Stock	0.00	0.00	10	222	254	297
Retained Earnings	-21	-17	-186	-250	-280	-331

This table presents TriSalus Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	34	18	32	27	29	41	36	71
Total Current Assets	29	13	28	24	25	38	33	68
Cash & Equivalents	21	3.97	16	11	13	26	23	57
Accounts Receivable	3.05	4.28	4.71	4.91	5.45	5.57	5.00	5.22
Inventories, net	1.63	2.91	3.44	4.00	4.16	3.81	3.28	3.78
Prepaid Expenses	2.98	2.03	3.31	3.61	2.48	2.22	2.37	2.59
Plant, Property, & Equipment, net	1.90	1.97	1.83	1.82	1.97	1.71	1.83	1.94
Total Noncurrent Assets	2.62	2.73	2.66	1.85	1.56	1.52	1.31	0.90
Other Noncurrent Operating Assets	1.62	1.62	1.55	1.85	1.56	1.52	1.31	0.90
Total Liabilities & Shareholders' Equity	34	18	32	27	29	41	36	71
Total Liabilities	25	53	57	48	63	61	63	58
Total Current Liabilities	9.31	14	12	9.92	12	9.32	11	12
Accounts Payable	1.90	2.35	1.98	1.45	2.81	1.90	3.78	4.23
Accrued Expenses	6.60	11	9.41	7.88	8.40	7.08	6.77	7.07
Other Current Liabilities	0.81	0.62	0.61	0.60	0.54	0.34	0.35	0.49
Total Noncurrent Liabilities	16	38	45	38	51	51	52	46
Long-Term Debt	-	-	21	22	32	32	33	33
Other Noncurrent Operating Liabilities	16	38	23	16	20	18	18	13
Commitments & Contingencies	0.00	-	-	-	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	8.49	-35	-24	-20	-34	-19	-27	13
Total Preferred & Common Equity	8.49	-35	-24	-20	-34	-19	-27	13
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	8.49	-35	-24	-20	-34	-19	-27	13
Common Stock	221	227	242	249	256	279	294	342
Retained Earnings	-213	-262	-266	-269	-290	-298	-321	-329

This table displays calculated financial ratios and metrics derived from TriSalus Life Sciences' official financial filings.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	62,500,000.00	31,250,000.00	26,316,681.00	-	49,964,311.00
DEI Adjusted Shares Outstanding	62,500,000.00	31,250,000.00	26,316,681.00	-	49,964,311.00
DEI Earnings Per Adjusted Shares Outstanding	0.08	-1.60	-2.42	-	-1.39
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	49.31%	58.99%	53.41%
EBITDA Growth	0.00%	-1,098.43%	-25.82%	57.02%	-25.23%
EBIT Growth	0.00%	-1,106.89%	-26.21%	54.24%	-25.15%
NOPAT Growth	0.00%	-738.86%	-49.50%	33.61%	25.49%
Net Income Growth	0.00%	-1,089.81%	-25.80%	49.39%	-30.56%
EPS Growth	0.00%	-53,950.00%	95.81%	80.65%	-40.46%
Operating Cash Flow Growth	0.00%	-1,759.08%	-56.53%	19.25%	55.90%
Free Cash Flow Firm Growth	0.00%	0.00%	-109.15%	-146.44%	80.81%
Invested Capital Growth	0.00%	-109.30%	-78.68%	68.24%	-72.31%
Revenue Q/Q Growth	0.00%	216.03%	-12.95%	9.44%	12.30%
EBITDA Q/Q Growth	0.00%	-12,423.97%	12.46%	52.19%	0.16%
EBIT Q/Q Growth	0.00%	-12,530.12%	12.01%	49.23%	1.78%
NOPAT Q/Q Growth	0.00%	-149.81%	19.35%	15.06%	13.79%
Net Income Q/Q Growth	0.00%	-183,885.78%	12.68%	45.69%	0.90%
EPS Q/Q Growth	0.00%	-535.27%	96.08%	-104.53%	8.00%
Operating Cash Flow Q/Q Growth	0.00%	-30.91%	-1.74%	6.71%	15.18%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-110.20%	-58.69%	41.54%
Invested Capital Q/Q Growth	0.00%	-109.03%	-201.19%	-22.81%	-42.50%
Profitability Metrics	-	-	-	-	-
Gross Margin	0.00%	81.79%	85.93%	86.06%	84.57%
EBITDA Margin	0.00%	-378.76%	-319.19%	-86.28%	-72.10%
Operating Margin	0.00%	-293.91%	-294.28%	-122.88%	-59.68%
EBIT Margin	0.00%	-381.97%	-322.88%	-92.94%	-75.81%
Profit (Net Income) Margin	0.00%	-380.60%	-320.69%	-102.09%	-86.88%
Tax Burden Percent	100.00%	100.02%	100.02%	100.02%	100.02%
Interest Burden Percent	101.36%	99.62%	99.31%	109.82%	114.57%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-24.08%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	453.93%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-18.63%	0.00%	0.00%	0.00%
Return on Equity (ROE)	2.06%	-42.71%	301.42%	113.47%	131.29%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-34.75%	-256.56%	-112.64%	-115.45%
Return on Assets (ROA)	0.00%	-34.63%	-254.82%	-123.72%	-132.30%
Return on Common Equity (ROCE)	-0.17%	37.32%	1,556.45%	113.47%	131.31%
Return on Equity Simple (ROE_SIMPLE)	-28.52%	26.76%	219.33%	116.03%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.04	-26	-38	-25	-19
NOPAT Margin	0.00%	-205.74%	-206.00%	-86.02%	-41.78%
Net Nonoperating Expense Percent (NNEP)	-2,275.61%	-478.01%	-200.37%	530.81%	155.66%
Return On Investment Capital (ROIC_SIMPLE)	-	-	140.89%	664.45%	2,314.38%
Cost of Revenue to Revenue	0.00%	18.21%	14.07%	13.94%	15.43%
SG&A Expenses to Revenue	0.00%	100.69%	127.02%	61.04%	47.53%
R&D to Revenue	0.00%	172.27%	161.17%	60.10%	33.14%
Operating Expenses to Revenue	0.00%	375.70%	380.21%	208.94%	144.25%
Earnings before Interest and Taxes (EBIT)	4.70	-47	-60	-27	-34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.70	-47	-59	-25	-33
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	25.28	12.01	5.19	7.72
Price to Earnings (P/E)	64.76	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.54%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.39	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	37.75	11.38	5.65	8.00
Enterprise Value to EBITDA (EV/EBITDA)	118.87	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	118.87	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	2.04	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	-0.85	-0.98
Long-Term Debt to Equity	0.00	0.00	0.00	-0.85	-0.98
Financial Leverage	0.00	-0.04	0.54	-0.03	-0.44
Leverage Ratio	1.09	1.23	-1.18	-0.92	-0.99
Compound Leverage Factor	1.10	1.23	-1.17	-1.01	-1.14
Debt to Total Capital	0.23%	0.00%	0.00%	-579.63%	-4,054.72%
Short-Term Debt to Total Capital	0.23%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	-579.63%	-4,054.72%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	106.92%	-1,330.79%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-7.15%	1,430.79%	100.00%	679.63%	4,155.21%
Debt to EBITDA	0.12	0.00	0.00	-0.87	-1.02
Net Debt to EBITDA	0.07	0.00	0.00	-0.53	-0.39
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.87	-1.02
Debt to NOPAT	-0.18	0.00	0.00	-0.87	-1.75
Net Debt to NOPAT	-0.11	0.00	0.00	-0.54	-0.67
Long-Term Debt to NOPAT	0.00	0.00	0.00	-0.87	-1.75
Altman Z-Score	10.70	-13.75	-18.58	-16.50	-11.29
Noncontrolling Interest Sharing Ratio	108.27%	187.37%	-416.38%	0.00%	-0.01%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.33	0.53	1.42	2.02	2.80
Quick Ratio	0.13	0.34	1.04	1.33	2.35
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	230	-21	-52	-9.94
Operating Cash Flow to CapEx	0.00%	-4,933.28%	-8,601.70%	-11,838.55%	-2,149.40%
Free Cash Flow to Firm to Interest Expense	0.00	229,856.71	-1,314.28	-16.77	-1.79
Operating Cash Flow to Interest Expense	0.00	-32,313.00	-3,161.13	-13.22	-3.25
Operating Cash Flow Less CapEx to Interest Expense	0.00	-32,968.00	-3,197.88	-13.33	-3.40
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.09	0.79	1.21	1.52
Accounts Receivable Turnover	0.00	0.00	7.24	6.81	7.75
Inventory Turnover	0.00	0.00	1.30	1.24	1.96
Fixed Asset Turnover	0.00	0.00	8.57	15.65	25.97
Accounts Payable Turnover	0.00	0.75	0.62	1.45	2.64
Days Sales Outstanding (DSO)	0.00	0.00	50.39	53.58	47.07
Days Inventory Outstanding (DIO)	0.00	0.00	281.35	293.25	186.69
Days Payable Outstanding (DPO)	0.00	485.32	584.14	251.98	138.24
Cash Conversion Cycle (CCC)	0.00	-485.32	-252.40	94.86	95.52
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	234	-22	-39	-12	-21
Invested Capital Turnover	0.00	0.12	-0.61	-1.15	-2.69
Increase / (Decrease) in Invested Capital	0.00	-255	-17	27	-8.92
Enterprise Value (EV)	559	468	211	166	361
Market Capitalization	309	313	222	153	349
Book Value per Share	($0.53)	($5.64)	($1.03)	($0.85)	($0.68)
Tangible Book Value per Share	($0.53)	($5.67)	($1.03)	($0.85)	($0.68)
Total Capital	234	-12	-27	-3.81	-0.82
Total Debt	0.54	0.00	0.00	22	33
Total Long-Term Debt	0.00	0.00	0.00	22	33
Net Debt	0.34	-9.41	-12	14	13
Capital Expenditures (CapEx)	0.00	0.66	0.59	0.35	0.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.73	-25	-5.60	1.92	0.31
Debt-free Net Working Capital (DFNWC)	-0.53	-15	6.18	10	21
Net Working Capital (NWC)	-1.08	-15	6.18	10	21
Net Nonoperating Expense (NNE)	-7.81	22	21	4.73	20
Net Nonoperating Obligations (NNO)	0.34	-9.41	-12	14	13
Total Depreciation and Amortization (D&A)	0.00	0.40	0.68	1.96	1.68
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-198.07%	-30.26%	6.51%	0.68%
Debt-free Net Working Capital to Revenue	0.00%	-122.14%	33.36%	35.48%	45.95%
Net Working Capital to Revenue	0.00%	-122.14%	33.36%	35.48%	45.95%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.30	$0.38	($6.73)	($1.31)	($1.84)
Adjusted Weighted Average Basic Shares Outstanding	31.25M	29.61M	9.40M	25.33M	37.90M
Adjusted Diluted Earnings per Share	$0.30	$0.38	($6.73)	($1.31)	($1.84)
Adjusted Weighted Average Diluted Shares Outstanding	31.25M	29.61M	9.40M	25.33M	37.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	31.25M	8.20M	0.00	32.27M	61.31M
Normalized Net Operating Profit after Tax (NOPAT)	-2.13	-26	-38	-25	-19
Normalized NOPAT Margin	0.00%	-205.74%	-206.00%	-86.02%	-41.78%
Pre Tax Income Margin	0.00%	-380.53%	-320.64%	-102.07%	-86.86%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	0.00	-47,357.00	-3,735.56	-8.85	-6.17
NOPAT to Interest Expense	0.00	-25,507.30	-2,383.28	-8.19	-3.40
EBIT Less CapEx to Interest Expense	0.00	-48,012.00	-3,772.31	-8.96	-6.33
NOPAT Less CapEx to Interest Expense	0.00	-26,162.30	-2,420.03	-8.30	-3.55
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.03%	0.00%	-3.95%

This table displays calculated financial ratios and metrics derived from TriSalus Life Sciences' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	7,394,794.00	26,316,681.00	26,316,681.00	27,159,327.00	29,311,498.00	-	64,544,924.00	37,838,962.00	49,867,279.00	49,964,311.00	61,306,437.00
DEI Adjusted Shares Outstanding	7,394,794.00	26,316,681.00	26,316,681.00	27,159,327.00	29,311,498.00	-	64,544,924.00	37,838,962.00	49,867,279.00	49,964,311.00	61,306,437.00
DEI Earnings Per Adjusted Shares Outstanding	-0.25	-1.39	-0.53	-0.19	-0.11	-	-0.17	-0.24	-0.83	-0.17	0.03
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	32.37%	-32.48%	116.39%	59.67%	41.52%	44.37%	41.97%	52.27%	57.38%	59.85%	-2.92%
EBITDA Growth	84.64%	18.75%	-61.78%	78.83%	2.48%	76.34%	32.70%	-113.50%	-691.97%	7.53%	136.77%
EBIT Growth	81.12%	18.50%	-60.09%	74.67%	7.74%	74.72%	30.52%	-97.52%	-571.09%	6.81%	130.48%
NOPAT Growth	-129.52%	47.74%	-15.32%	28.51%	53.06%	47.10%	37.21%	10.30%	-3.15%	56.85%	-63.52%
Net Income Growth	82.39%	19.45%	-59.72%	69.00%	-68.35%	71.72%	21.44%	-91.32%	-350.65%	3.51%	114.83%
EPS Growth	99.46%	121.91%	-5.26%	99.41%	14.29%	-101.28%	35.00%	-28.57%	-700.00%	42.11%	107.69%
Operating Cash Flow Growth	5.32%	-10.43%	-3.47%	-45.32%	49.93%	37.81%	58.60%	45.46%	65.81%	56.47%	-44.03%
Free Cash Flow Firm Growth	1,587.11%	-97.00%	-82.79%	-94.85%	-103.73%	-548.50%	-174.11%	-203.69%	83.96%	120.84%	52.76%
Invested Capital Growth	-105.36%	-78.68%	-616.34%	-1,105.17%	22.12%	68.24%	59.71%	37.88%	-48.50%	-72.31%	31.93%
Revenue Q/Q Growth	12.60%	10.19%	12.85%	14.05%	-0.20%	12.41%	10.97%	22.32%	3.15%	14.17%	-32.61%
EBITDA Q/Q Growth	90.97%	-2,767.47%	63.43%	77.64%	58.40%	-891.47%	-1.16%	26.86%	-54.30%	16.48%	140.22%
EBIT Q/Q Growth	89.02%	-2,238.06%	63.01%	73.33%	60.00%	-540.69%	-1.51%	24.18%	-35.90%	10.91%	133.20%
NOPAT Q/Q Growth	-62.81%	23.16%	18.40%	29.97%	-6.91%	13.41%	3.31%	-0.04%	-22.94%	63.71%	-266.39%
Net Income Q/Q Growth	89.80%	-2,404.98%	63.00%	67.20%	44.62%	-320.80%	-2.64%	20.12%	-30.44%	9.79%	115.78%
EPS Q/Q Growth	99.61%	21,371.43%	-102.01%	65.00%	42.86%	-216.67%	-2.63%	30.77%	-255.56%	77.08%	113.64%
Operating Cash Flow Q/Q Growth	-134.54%	57.64%	-18.42%	-23.51%	19.18%	47.39%	21.17%	-62.70%	49.33%	33.03%	-160.87%
Free Cash Flow Firm Q/Q Growth	2.99%	-97.05%	439.47%	-68.59%	-174.64%	-254.59%	10.88%	56.05%	88.45%	560.75%	-302.03%
Invested Capital Q/Q Growth	-703.44%	-201.19%	-0.13%	50.26%	48.08%	-22.81%	-27.05%	23.32%	-24.13%	-42.50%	49.81%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.66%	89.83%	84.96%	87.62%	86.34%	85.28%	83.69%	83.93%	83.52%	86.66%	86.18%
EBITDA Margin	-24.09%	-626.91%	-203.14%	-39.83%	-16.60%	-102.74%	-96.30%	-55.85%	-83.54%	-61.11%	36.48%
Operating Margin	-358.48%	-249.98%	-180.77%	-111.00%	-118.91%	-91.60%	-79.95%	-65.39%	-77.94%	-24.77%	-94.52%
EBIT Margin	-29.60%	-628.03%	-205.85%	-48.14%	-19.30%	-109.97%	-100.74%	-62.45%	-82.28%	-64.20%	31.63%
Profit (Net Income) Margin	-27.44%	-623.84%	-204.52%	-58.83%	-32.64%	-122.20%	-113.18%	-73.91%	-93.47%	-73.86%	17.29%
Tax Burden Percent	100.00%	100.00%	100.02%	100.16%	99.88%	99.99%	100.05%	99.96%	100.05%	100.00%	99.74%
Interest Burden Percent	92.71%	99.33%	99.33%	122.00%	169.39%	111.13%	112.29%	118.41%	113.56%	115.04%	54.81%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.26%
Return on Invested Capital (ROIC)	-46.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-163.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	13.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-33.72%	301.42%	449.45%	401.56%	931.33%	113.47%	78.55%	143.07%	167.87%	131.29%	253.33%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-4.42%	-499.02%	-235.65%	-53.32%	-17.00%	-133.28%	-139.22%	-60.95%	-103.47%	-97.76%	28.51%
Return on Assets (ROA)	-4.10%	-495.69%	-234.12%	-65.15%	-28.77%	-148.10%	-156.41%	-72.14%	-117.56%	-112.47%	15.59%
Return on Common Equity (ROCE)	0.43%	1,556.45%	766.19%	579.24%	931.64%	113.47%	78.55%	143.07%	167.88%	131.31%	253.33%
Return on Equity Simple (ROE_SIMPLE)	-801.04%	0.00%	184.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-10	-8.17	-5.72	-6.12	-5.30	-5.13	-5.13	-6.31	-2.29	-8.39
NOPAT Margin	-250.94%	-174.99%	-126.54%	-77.70%	-83.24%	-64.12%	-55.96%	-45.77%	-54.55%	-17.34%	-94.27%
Net Nonoperating Expense Percent (NNEP)	116.37%	-242.40%	-366.55%	-44.30%	67.65%	538.51%	71.22%	51.68%	40.55%	57.05%	415.84%
Return On Investment Capital (ROIC_SIMPLE)	-	37.00%	23.40%	199.85%	-491.74%	139.03%	192.07%	-36.36%	-86.79%	280.94%	-18.28%
Cost of Revenue to Revenue	11.34%	10.17%	15.04%	12.38%	13.66%	14.72%	16.31%	16.07%	16.48%	13.34%	13.82%
SG&A Expenses to Revenue	173.79%	105.54%	71.66%	53.72%	64.32%	56.36%	57.23%	50.45%	57.57%	31.59%	61.25%
R&D to Revenue	183.05%	136.33%	90.51%	63.36%	57.41%	35.66%	32.96%	34.99%	44.75%	19.46%	36.14%
Operating Expenses to Revenue	447.14%	339.81%	265.73%	198.61%	205.25%	176.88%	163.64%	149.32%	161.46%	111.43%	180.69%
Earnings before Interest and Taxes (EBIT)	-1.54	-36	-13	-3.55	-1.42	-9.09	-9.24	-7.00	-9.52	-8.48	2.82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.25	-36	-13	-2.93	-1.22	-8.49	-8.83	-6.26	-9.66	-8.07	3.25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.15
Price to Tangible Book Value (P/TBV)	5.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.15
Price to Revenue (P/Rev)	1.78	12.01	11.67	6.06	5.02	5.19	5.24	4.89	5.77	7.72	5.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.78	11.38	11.49	6.26	5.41	5.65	5.82	5.08	6.05	8.00	4.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.08	0.00	35.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	-0.88	-1.06	-0.85	-0.92	-1.73	-1.27	-0.98	2.58
Long-Term Debt to Equity	0.00	0.00	0.00	-0.88	-1.06	-0.85	-0.92	-1.73	-1.27	-0.98	2.58
Financial Leverage	-0.08	0.54	0.10	-0.23	0.92	-0.03	-0.21	-0.28	-0.47	-0.44	0.22
Leverage Ratio	1.15	-1.18	-1.34	-1.64	-5.11	-0.92	-0.67	-1.69	-1.36	-0.99	-4.62
Compound Leverage Factor	1.07	-1.18	-1.33	-2.00	-8.65	-1.02	-0.75	-2.00	-1.54	-1.14	-2.53
Debt to Total Capital	0.00%	0.00%	0.00%	-743.49%	1,742.60%	-579.63%	-1,186.78%	237.60%	467.61%	-4,054.72%	72.09%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	-743.49%	1,742.60%	-579.63%	-1,186.78%	237.60%	467.61%	-4,054.72%	72.09%
Preferred Equity to Total Capital	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.99%	100.00%	100.00%	843.49%	-1,642.85%	679.63%	1,286.78%	-137.60%	-367.61%	4,155.21%	27.91%
Debt to EBITDA	0.00	0.00	0.00	-0.40	-0.41	-0.87	-1.46	-1.39	-1.04	-1.02	-1.62
Net Debt to EBITDA	0.00	0.00	0.00	-0.09	-0.20	-0.53	-0.86	-0.29	-0.35	-0.39	1.15
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.40	-0.41	-0.87	-1.46	-1.39	-1.04	-1.02	-1.62
Debt to NOPAT	0.00	0.00	0.00	-0.58	-0.72	-0.87	-1.42	-1.55	-1.55	-1.75	-1.69
Net Debt to NOPAT	0.00	0.00	0.00	-0.13	-0.35	-0.54	-0.84	-0.33	-0.52	-0.67	1.20
Long-Term Debt to NOPAT	0.00	0.00	0.00	-0.58	-0.72	-0.87	-1.42	-1.55	-1.55	-1.75	-1.69
Altman Z-Score	-6.79	-15.39	-18.86	-8.90	-10.62	-13.99	-11.96	-7.22	-9.14	-8.88	-2.24
Noncontrolling Interest Sharing Ratio	101.28%	-416.38%	-70.47%	-44.25%	-0.03%	0.00%	0.00%	0.00%	-0.01%	-0.01%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.12	1.42	0.92	2.33	2.40	2.02	2.14	4.08	3.05	2.80	5.78
Quick Ratio	2.63	1.04	0.57	1.77	1.63	1.33	1.57	3.44	2.54	2.35	5.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	240	7.09	38	12	-8.97	-32	-28	-12	-1.44	6.63	-13
Operating Cash Flow to CapEx	-12,169.66%	-2,466.94%	-16,465.15%	-22,370.00%	-6,418.34%	-11,414.00%	-630.11%	0.00%	-2,107.39%	-6,058.54%	-4,595.74%
Free Cash Flow to Firm to Interest Expense	60,116.63	2,363.73	12,751.67	13.70	-7.85	-29.78	-23.45	-8.76	-0.99	4.57	-9.33
Operating Cash Flow to Interest Expense	-5,415.50	-3,059.00	-3,622.33	-15.30	-9.50	-5.34	-3.72	-5.14	-2.54	-1.71	-4.51
Operating Cash Flow Less CapEx to Interest Expense	-5,460.00	-3,183.00	-3,644.33	-15.37	-9.65	-5.39	-4.31	-5.08	-2.66	-1.74	-4.61
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.15	0.79	1.14	1.11	0.88	1.21	1.38	0.98	1.26	1.52	0.90
Accounts Receivable Turnover	0.00	7.24	0.00	0.00	6.75	6.81	6.61	7.00	8.11	7.75	8.41
Inventory Turnover	0.00	1.30	0.00	0.00	1.23	1.24	1.31	1.52	1.76	1.96	1.69
Fixed Asset Turnover	0.00	8.57	0.00	0.00	14.48	15.65	16.34	20.33	22.07	25.97	22.96
Accounts Payable Turnover	2.65	0.62	1.48	1.31	2.07	1.45	1.80	2.85	2.45	2.64	1.90
Days Sales Outstanding (DSO)	0.00	50.39	0.00	0.00	54.05	53.58	55.25	52.11	44.99	47.07	43.38
Days Inventory Outstanding (DIO)	0.00	281.35	0.00	0.00	296.08	293.25	279.06	239.83	206.84	186.69	216.28
Days Payable Outstanding (DPO)	137.91	584.14	246.87	277.65	175.98	251.98	203.29	128.28	148.70	138.24	191.71
Cash Conversion Cycle (CCC)	-137.91	-252.40	-246.87	-277.65	174.15	94.86	131.02	163.66	103.13	95.52	67.95
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-13	-39	-39	-19	-10	-12	-16	-12	-15	-21	-11
Invested Capital Turnover	0.19	-0.61	-1.40	-2.36	-2.34	-1.15	-1.18	-2.30	-3.22	-2.69	-3.41
Increase / (Decrease) in Invested Capital	-253	-17	-46	-18	2.85	27	23	7.33	-4.87	-8.92	5.00
Enterprise Value (EV)	16	211	253	155	146	166	187	183	243	361	222
Market Capitalization	38	222	257	150	135	153	168	176	232	349	245
Book Value per Share	$1.15	($1.03)	($1.33)	($0.89)	($0.70)	($0.85)	($1.13)	($0.60)	($0.54)	($0.68)	$0.21
Tangible Book Value per Share	$1.01	($1.03)	($1.37)	($0.93)	($0.70)	($0.85)	($1.13)	($0.60)	($0.54)	($0.68)	$0.21
Total Capital	8.49	-27	-35	-2.86	1.24	-3.81	-2.67	14	7.27	-0.82	46
Total Debt	0.00	0.00	0.00	21	22	22	32	34	34	33	33
Total Long-Term Debt	0.00	0.00	0.00	21	22	22	32	34	34	33	33
Net Debt	-21	-12	-3.97	4.81	10	14	19	7.05	11	13	-23
Capital Expenditures (CapEx)	0.18	0.37	0.07	0.06	0.17	0.05	0.71	-0.09	0.18	0.04	0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.65	-5.60	-5.17	-0.54	2.60	1.92	0.34	2.27	-0.27	0.31	-0.20
Debt-free Net Working Capital (DFNWC)	20	6.18	-1.20	16	14	10	13	29	22	21	56
Net Working Capital (NWC)	20	6.18	-1.20	16	14	10	13	29	22	21	56
Net Nonoperating Expense (NNE)	-12	26	5.04	-1.39	-3.72	4.80	5.24	3.16	4.50	7.46	-9.93
Net Nonoperating Obligations (NNO)	-21	-12	-3.97	4.81	10	14	19	7.41	12	13	-23
Total Depreciation and Amortization (D&A)	0.29	0.06	0.18	0.61	0.20	0.60	0.41	0.74	-0.15	0.41	0.43
Debt-free, Cash-free Net Working Capital to Revenue	-7.75%	-30.26%	-23.53%	-2.17%	9.68%	6.51%	1.07%	6.31%	-0.67%	0.68%	-0.45%
Debt-free Net Working Capital to Revenue	92.81%	33.36%	-5.47%	64.46%	51.65%	35.48%	41.51%	79.91%	55.76%	45.95%	125.55%
Net Working Capital to Revenue	92.81%	33.36%	-5.47%	64.46%	51.65%	35.48%	41.51%	79.91%	55.76%	45.95%	125.55%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.13)	$29.78	($0.60)	($0.21)	($0.12)	($0.38)	($0.39)	($0.27)	($0.96)	($0.22)	$0.03
Adjusted Weighted Average Basic Shares Outstanding	13.17M	9.40M	23.32M	23.90M	26.50M	25.33M	28.53M	32.90M	43.06M	37.90M	51.54M
Adjusted Diluted Earnings per Share	($0.13)	$29.78	($0.60)	($0.21)	($0.12)	($0.38)	($0.39)	($0.27)	($0.96)	($0.22)	$0.03
Adjusted Weighted Average Diluted Shares Outstanding	13.17M	9.40M	23.32M	23.90M	26.50M	25.33M	28.53M	32.90M	43.06M	37.90M	52.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.32M	0.00	27.16M	29.31M	30.49M	32.27M	37.84M	49.87M	49.96M	61.31M	61.42M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-10	-8.17	-5.72	-6.12	-5.30	-5.13	-5.13	-6.31	-2.29	-8.39
Normalized NOPAT Margin	-250.94%	-174.99%	-126.54%	-77.70%	-83.24%	-64.12%	-55.96%	-45.77%	-54.55%	-17.34%	-94.27%
Pre Tax Income Margin	-27.44%	-623.82%	-204.48%	-58.73%	-32.68%	-122.21%	-113.12%	-73.94%	-93.43%	-73.86%	17.34%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-384.25	-11,978.67	-4,430.67	-4.04	-1.24	-8.51	-7.64	-4.92	-6.52	-5.84	1.96
NOPAT to Interest Expense	-3,257.80	-3,337.60	-2,723.47	-6.52	-5.36	-4.96	-4.24	-3.61	-4.32	-1.58	-5.84
EBIT Less CapEx to Interest Expense	-428.75	-12,102.67	-4,452.67	-4.11	-1.39	-8.55	-8.23	-4.86	-6.64	-5.87	1.86
NOPAT Less CapEx to Interest Expense	-3,302.30	-3,461.60	-2,745.47	-6.59	-5.50	-5.01	-4.83	-3.54	-4.44	-1.61	-5.94
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.03%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.97%	-3.91%	-3.95%	0.00%

Financials Breakdown Chart

TriSalus Life Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TriSalus Life Sciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

TriSalus Life Sciences' net income appears to be on an upward trend, with a most recent value of -$39.23 million in 2025, falling from $4.77 million in 2021. The previous period was -$30.05 million in 2024. View TriSalus Life Sciences' forecast to see where analysts expect TriSalus Life Sciences to go next.

TriSalus Life Sciences' total operating income in 2025 was -$26.95 million, based on the following breakdown:

Total Gross Profit: $38.19 million
Total Operating Expenses: $65.13 million

Over the last 4 years, TriSalus Life Sciences' total revenue changed from $0.00 in 2021 to $45.15 million in 2025, a change of 4,515,100,000.0%.

TriSalus Life Sciences' total liabilities were at $69.19 million at the end of 2025, a 38.8% increase from 2024, and a 194.5% increase since 2020.

In the past 5 years, TriSalus Life Sciences' cash and equivalents has ranged from $200.88 thousand in 2021 to $20.44 million in 2025, and is currently $20.44 million as of their latest financial filing in 2025.

Over the last 4 years, TriSalus Life Sciences' book value per share changed from -0.53 in 2021 to -0.68 in 2025, a change of 26.7%.

Related Companies

Financial statements for NASDAQ:TLSI last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TriSalus Life Sciences (TLSI) Financials

Financials Breakdown Chart

TriSalus Life Sciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TriSalus Life Sciences (TLSI) Financials

Annual Income Statements for TriSalus Life Sciences

Quarterly Income Statements for TriSalus Life Sciences

Annual Cash Flow Statements for TriSalus Life Sciences

Quarterly Cash Flow Statements for TriSalus Life Sciences

Annual Balance Sheets for TriSalus Life Sciences

Quarterly Balance Sheets for TriSalus Life Sciences

Annual Metrics And Ratios for TriSalus Life Sciences

Quarterly Metrics And Ratios for TriSalus Life Sciences

Financials Breakdown Chart

TriSalus Life Sciences Financials - Frequently Asked Questions

When does TriSalus Life Sciences' fiscal year end?

How has TriSalus Life Sciences' net income changed over the last 4 years?

What is TriSalus Life Sciences' operating income?

How has TriSalus Life Sciences' revenue changed over the last 4 years?

How much debt does TriSalus Life Sciences have?

How much cash does TriSalus Life Sciences have?

How has TriSalus Life Sciences' book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools